KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables - Net: 2009-2024

Historic Receivables - Net for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $660.5 million.

  • Biomarin Pharmaceutical's Receivables - Net rose 1.64% to $790.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $790.3 million, marking a year-over-year increase of 1.64%. This contributed to the annual value of $660.5 million for FY2024, which is 4.23% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Receivables - Net is $660.5 million, which was up 4.23% from $633.7 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Receivables - Net high stood at $660.5 million for FY2024, and its period low was $373.4 million during FY2021.
  • Moreover, its 3-year median value for Receivables - Net was $633.7 million (2023), whereas its average is $585.2 million.
  • In the last 5 years, Biomarin Pharmaceutical's Receivables - Net dropped by 16.72% in 2021 and then skyrocketed by 37.37% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Receivables - Net (Yearly) stood at $448.4 million in 2020, then dropped by 16.72% to $373.4 million in 2021, then climbed by 23.55% to $461.3 million in 2022, then surged by 37.37% to $633.7 million in 2023, then climbed by 4.23% to $660.5 million in 2024.